Modern Slavery statement

World Academy of Medical Leadership

Modern Slavery and Human Trafficking Statement

Financial Year Ending: 31 March 2025

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes the slavery and human trafficking statement for the World Academy of Medical Leadership (“the Company”), including its trading arm, the National Autism Assessment Centre (“NAAC”), for the financial year ending 2025.

The Company confirms that this statement has been approved by the Board of Directors and complies with the requirements of section 54 of the Modern Slavery Act 2015 and with any guidance issued under that section.

 

  1. Our Organisation

The World Academy of Medical Leadership is a UK-registered company  (company number 11680322) with operations in health, education, training, and clinical assessment services. The National Autism Assessment Centre operates as its trading arm, delivering autism diagnostic and related assessment services across the UK.

We are committed to acting ethically and with integrity in all of our operations and to ensuring that slavery and human trafficking are not present in our supply chains or in any part of our business.

 

  1. Our Supply Chains

Our supply chains are relatively limited and primarily comprise:

  • Employment of healthcare professionals and administrative staff;
  • Procurement of medical equipment, IT systems, and office supplies;
  • Use of contracted clinical spaces and professional services (legal, financial, training).

We recognise that risks may exist, particularly in outsourced services, agency staffing, and procurement of goods (e.g., IT equipment, uniforms, consumables).

 

  1. Our Policies on Modern Slavery and Human Trafficking

We have adopted a Modern Slavery and Human Trafficking Policy, which underpins our commitment to preventing exploitation and to safeguarding vulnerable people. The policy is aligned with UK legislation and NHS best practice standards.

The policy commits us to:

  • Zero tolerance of slavery, servitude, forced labour, or human trafficking in our operations;
  • Due diligence in supplier selection and contracting;
  • Whistleblowing protections for staff to raise concerns;
  • Ongoing monitoring and risk assessment.

 

  1. Due Diligence Processes

To identify and mitigate risk, we have implemented due diligence measures:

  • Vetting of all staff, contractors, and locums through right to work checks, DBS checks, and professional registration verification;
  • Supplier questionnaires requiring compliance with the Modern Slavery Act;
  • Risk-based supplier reviews, prioritising sectors at higher risk of labour exploitation (e.g., agency staff, cleaning, catering, IT hardware supply).

 

  1. Risk Assessment and Management

We continually assess potential risks of modern slavery and human trafficking within our operations and supply chain. Our current assessment indicates low direct risk, but we remain vigilant, especially in:

  • Use of temporary and locum staff supplied through agencies;
  • Procurement of manufactured goods from global markets.

Where risks are identified, we will engage with suppliers, require corrective action, or terminate relationships if compliance cannot be assured.

 

  1. Training and Awareness

We recognise the importance of equipping staff to identify and respond to risks. We are introducing:

  • Induction training on modern slavery awareness for all new employees;
  • Targeted training for managers and procurement staff;
  • Access to national NHS safeguarding training modules which cover exploitation and trafficking.

 

  1. Effectiveness and Performance Review

We measure our effectiveness through:

  • Annual review of supplier compliance statements;
  • Monitoring concerns raised through safeguarding and whistleblowing channels;
  • Regular policy updates in line with Home Office guidance.

 

  1. Approval

This statement has been approved by the Board of Directors of the World Academy of Medical Leadership on [insert date] and is signed on its behalf by:

Dr Jill Aylott

CEO,

World Academy of Medical Leadership

Date: 28 August 2025